[Federal Register Volume 68, Number 106 (Tuesday, June 3, 2003)]
[Notices]
[Pages 33125-33129]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-13721]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[OPPT-2003-0010; FRL-7300-6]


1,2-Ethylene Dichloride; Final Enforceable Consent Agreement and 
Testing Consent Order

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Under section 4 of the Toxic Substances Control Act (TSCA), 
EPA has issued a testing consent order (Order) that incorporates an 
enforceable consent agreement (ECA) with the Dow Chemical Company, 
Vulcan Materials Company, Occidental Chemical Corporation, Oxy Vinyls, 
LP, Georgia Gulf Corporation, Westlake Chemical Corporation, PPG 
Industries, Inc., and Formosa Plastics Corporation, U.S.A. The 
Companies are members of the Hazardous Air Pollutant (HAP) Task Force, 
which represents the manufacturers of 1,2-ethylene dichloride (EDC). 
The Companies have agreed to: Conduct toxicity testing, develop 
pharmacokinetics and mechanistic test data, and develop a computational 
dosimetry model for quantitative route-to-route extrapolations of dose-
response for EDC for acute, subchronic, developmental, reproductive and 
neurotoxicity effects that were identified in a proposed test rule for 
hazardous air pollutants. This notice announces the ECA and Order for 
EDC and summarizes the terms of the ECA.

DATES: The effective date of the ECA and Order is May 13, 2003.

FOR FURTHER INFORMATION CONTACT: For general information contact: 
Barbara Cunningham, Acting Director, Environmental Assistance Division 
(7408M), Office of Pollution Prevention and Toxics, Environmental 
Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-
0001; telephone number: (202) 554-1404; e-mail address: [email protected].
    For technical information contact: Richard Leukroth or John 
Schaeffer, Chemical Control Division (7405M), Office of Pollution 
Prevention and Toxics, Environmental Protection Agency, 1200 
Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: 
(202) 564-8157; fax number: (202) 564-4765; e-mail address: 
[email protected].

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

    This announcement is directed to the public in general. However, as 
described in Unit IV., this ECA and Order may affect others in that EPA 
has initiated rulemaking under TSCA section 12(b) (62 FR 67038, 
December 23, 1997) (FRL-5762-8). When finalized, that rulemaking will 
require all persons who export or intend to export EDC to comply with 
the export notification regulations at 40 CFR part 707, subpart D. 
Although others may be affected by subsequent actions related to this 
announcement, this ECA and Order only applies to those Companies that 
are specifically named in this ECA and Order. If you have any questions 
regarding the applicability of this action to a particular entity, 
consult the technical person listed under FOR FURTHER INFORMATION 
CONTACT.

[[Page 33126]]

B. How Can I Get Copies of this Document and Other Related Information?

    1. Docket. EPA has established an official public docket for this 
action under docket identification (ID) number OPPT-2003-0010. The 
official public docket consists of the documents specifically 
referenced in this action, any public comments received, and other 
information related to this action. Although a part of the official 
docket, the public docket does not include Confidential Business 
Information (CBI) or other information whose disclosure is restricted 
by statute. The official public docket is the collection of materials 
that is available for public viewing at the EPA Docket Center, Rm. 
B102-Reading Room, EPA West, 1301 Constitution Ave., NW., Washington, 
DC. The EPA Docket Center is open from 8:30 a.m. to 4:30 p.m., Monday 
through Friday, excluding legal holidays. The EPA Docket Center Reading 
Room telephone number is (202) 566-1744 and the telephone number for 
the OPPT Docket, which is located in the EPA Docket Center, is (202) 
566-0280.
    2. Electronic access. You may access this Federal Register document 
electronically through the EPA Internet under the ``Federal Register'' 
listings at http://www.epa.gov/fedrgstr/.
    An electronic version of the public docket is available through 
EPA's electronic public docket and comment system, EPA Dockets. You may 
use EPA Dockets at http://www.epa.gov/edocket/ to submit or view public 
comments, access the index listing of the contents of the official 
public docket, and to access those documents in the public docket that 
are available electronically. Although not all docket materials may be 
available electronically, you may still access any of the publicly 
available docket materials through the docket facility identified in 
Unit I.B.1. Once in the system, select ``search,'' then key in the 
appropriate docket ID number.

II. Background

A. What is EDC?

    EDC is used as a chemical intermediate principally in the 
production of vinyl chloride, but also vinylidene chloride, 1,1,1-
trichloroethane, trichloroethylene, tetrachloroethylene, aziridines, 
and ethylene diamines. It is also used as a solvent. An estimated 
77,111 workders are exposed to EDC (Ref. 1). The Chemical Abstract 
Service Registry Number (CAS No.) for EDC is 107-06-2.

B. Why Does EPA Need Health Effects Data on EDC?

    EPA proposed health effects testing under TSCA section 4(a) for a 
number of hazardous air pollutants (``HAPs'' or ``HAP chemicals''), 
including EDC (61 FR 33178, June 26, 1996) (FRL-4869-1), as amended at 
62 FR 67466, December 24, 1997 (FRL-5742-2) and 63 FR 19694, April 21, 
1998 (FRL-5780-6). In the original HAPs proposal, the Agency made 
preliminary findings for EDC (61 FR 33178, 33190, 33191; and Ref. 1) 
that:
    1. EDC may present an unreasonable risk of injury to health.
    2. EDC is or will be produced in substantial quantities, and there 
is or may be substantial human exposures to the chemical.
    3. There are insufficient data to determine or predict the effects 
of activities on human health involving EDC.
    4. Testing is necessary to develop health effects data for EDC.
    The HAPs rule, as amended, proposed testing of EDC for acute 
toxicity, subchronic toxicity, developmental toxicity, reproductive 
effects toxicity, and neurotoxicity (61 FR 33178, 33198, June 26, 1996; 
62 FR 67466, 67483, December 24, 1997).

III. ECA Development and Conclusion

A. How is EPA Going to Obtain Health Effects Testing on EDC?

    In the proposed HAPs test rule, as amended, EPA invited the 
submission of proposals regarding the performance of pharmacokinetics 
studies that would permit extrapolation from oral data to predict risk 
from inhalation exposure. Such proposals could provide the scientific 
basis for alternative testing to the testing proposed and form the 
basis for developing needed HAPs data via ECAs (61 FR 33178, 33189, 
June 26, 1996; 62 FR 67466, 67474, December 24, 1997). EPA uses ECAs to 
accomplish testing where a consensus exists among EPA, affected 
manufacturers and/or processors, and interested members of the public 
concerning the need for and scope of testing (40 CFR 790.1(c)).
    The procedures for ECA development are described at 40 CFR 
790.22(b).
    In response to EPA's request for proposals for ECAs, the HAP Task 
Force submitted a proposal for alternative testing that included 
physiologically-based pharmacokinetics (PBPK) studies and computational 
modeling to inform route-to-route extrapolations of dose-response for 
EDC on November 22, 1996 (Ref. 2). EPA responded to this proposal on 
June 26, 1997 (Ref. 3), indicating that the HAP Task Force alternative 
approach offered sufficient merit to proceed with discussions for 
developing an ECA for EDC. Consequently, EPA issued a document which 
was published in the Federal Register of December 19, 1997 (62 FR 
66626) (FRL-5763-1), soliciting interested parties to monitor or 
participate in these discussions.
    EPA held a public meeting to develop an ECA for EDC on January 12, 
1998. Representatives of the Companies and other interested parties 
attended this meeting. The participants reached consensus on the 
general scope of the testing to be required under the ECA. Following 
the public meeting, the HAP Task Force submitted (March 19, 1999) a 
revised proposal for a testing program (Ref. 4). On February 13, 2001, 
EPA responded to the HAP Task Force with comments on the revised 
proposal and by initiating a draft ECA for consideration by the HAP 
Task Force (Ref. 5). A final version of the ECA was later circulated to 
the HAP Task Force for signature, and returned to EPA for signature. On 
February 3, 2003, EPA received the ECA signed by the Companies. On May 
13, 2003, EPA signed the ECA and accompanying Order (Ref. 6).

B. What Testing Does the ECA for EDC Require?

    The EDC ECA alternative testing program has four segments as 
follows: Tier I HAPs Testing, Tier I Program Review Testing, EPA 
Program Review, and Tier II Testing. This is described in Table 1 in 
this unit and includes the following testing, reporting, and review 
activities:
    1. Tier I HAPs Testing. This testing consists of endpoint testing, 
conducted by inhalation exposure, that EPA deemed necessary to meet 
certain data needs identified in the proposed HAPs test rule, as 
amended, and includes acute toxicity with bronchoalveolar lavage (BAL) 
and histopathology, and acute neurotoxicity testing. These tests will 
be conducted under a combined protocol as described in Appendix D.1 of 
the ECA.
    2. Tier I Program Review Testing. Under this segment of the EDC ECA 
alternative testing program, the Companies will conduct studies to 
extend the computational dosimetry model of D'Souza et al. (1987; 1988; 
Refs. 7 and 8) in order to apply the model to the specific health 
effects endpoints for EDC listed in the ECA, validate the model, and 
verify the model's ability to perform quantitative route-to-route 
extrapolations of dose-response. In addition, the Companies will 
sponsor development of

[[Page 33127]]

pharmacokinetics and mechanistic (PK/MECH) data to support the 
application of the model for the endpoints listed under Tier II of the 
EDC ECA. Specifically, the PK/MECH testing will develop data to inform:
    i. Oral-to-inhalation extrapolation of subchronic toxicity data 
reported by Daniel, et al. (1994; Ref. 9) relevant to corn oil gavage.
    ii. Oral-to-inhalation extrapolation of subchronic neurotoxicity 
data relevant to drinking water exposure of a study to be conducted 
under Tier II Testing.
    iii. Oral-to-inhalation extrapolation of reproductive effects 
testing conducted under Tier II Testing and each dosing paradigm of 
studies reported by Alumot et al. (1976; Ref. 10), Rao, et al. (1980; 
Ref. 11) and Lane et al. (1982; Ref. 12).
    In addition, the Companies will provide model simulations with 
point and uncertainty estimates of internal dose metrics (parent 
chemical peak and area under the curve (AUC) concentrations in blood 
and brain, and 24-hour total glutathione-dependent metabolism) in rats 
and humans to inform quantitative route-to-route extrapolations of 
dose-response. These simulations will be used to evaluate the 
acceptability of: Subchronic neurotoxicity testing of oral exposure via 
drinking water in rats, extant oral subchronic toxicity data of Daniel 
et al. (1994; Ref. 9) in rats via corn oil gavage, and reproductive 
toxicity testing of oral exposure via drinking water in rats.
    3. EPA Program Review. Model development and data from Tier I 
Program Review Testing are subject to an EPA Program Review. It is 
essential to the success of the EDC ECA alternative testing program for 
EPA to ensure that the model and the PK/MECH data used to support the 
route-to-route extrapolations of dose-response are of the highest 
quality. The purpose of the EPA Program Review will be to determine:
    i. Whether it is feasible and appropriate to apply Tier I Program 
Review Testing data and data from other studies acceptable to EPA to 
support computational route-to-route extrapolations of dose-response 
for endpoints listed in the Tier II Testing segment of the ECA.
    ii. Whether the data from the Tier I Program Review Testing segment 
provide a sufficient basis for conducting the endpoint testing and/or 
the computational route-to-route extrapolations for the dose-responses 
specified in the Tier II Testing segment.
    iii. The nature and scope of any additional work that may be 
required before Tier II Testing and application of the EDC model for 
route-to-route extrapolation of dose-response reporting (e.g., 
development of additional PK/MECH data, modification to the EDC model).
    4. Tier II Testing and/or Extrapolation Reporting. This segment of 
the EDC ECA alternative testing program consists of endpoint testing by 
drinking water exposure for subchronic neurotoxicity and reproductive 
toxicity. The reproductive effects toxicity testing is intended to 
confirm studies reported by Alumot et al. (1976; Ref. 10), Rao et al. 
(1980; Ref. 11), and Lane et al. (1982; Ref. 12), and provide data 
needed on fertility index, gestation index, gross necropsy, organ 
weight, histopathology, estrous cycle, sperm evaluation, vaginal 
opening, and preputial separation as described in the ECA.
    This segment will also include application of the EDC model for 
quantitative route-to-route extrapolation reporting (oral to 
inhalation) for Tier II endpoint testing (subchronic neurotoxicity and 
reproductive toxicity) and similar computational extrapolation 
reporting for extant subchronic toxicity reported by Daniel et al. 
(1994; Ref. 9).
    Testing conducted under this ECA will allow EPA to characterize 
certain potential health hazards resulting from inhalation exposure to 
EDC. The following Table 1 sets forth the required testing, test 
standard, and reporting requirements under the ECA for EDC.

                  Table 1.--Required Testing, Test Standard, and Reporting Requirements for EDC
----------------------------------------------------------------------------------------------------------------
                                                                                                  Deadline for
           Testing Segment                   Required testing              Test standard        final report\1\
                                                                                                    (Months)
----------------------------------------------------------------------------------------------------------------
Tier I HAPs Testing.                   Acute toxicity, with BAL and  40 CFR 799.9135 (as                      18
                                        histopathology                annotated in ECA
                                        (inhalation).                 Appendix D.1).
                                       Acute neurotoxicity           40 CFR 799.9620 (as                      18
                                        (inhalation).                 annotated in ECA
                                                                      Appendix D.1).
-----------------------------------------------------------------------------------------------
Tier I Program Review Testing.         PK/MECH data to support       ECA Appendix C (1-4).                    21
                                        model validation and
                                        verification of oral-to-
                                        inhalation extrapolation of
                                        dose-response for the
                                        following data needs in the
                                        F344 rat:
                                       a. Subchronic toxicity.
                                       b. Subchronic neurotoxicity.
                                       c. Reproductive toxicity.
                                       PBPK model simulations.       ECA Appendix C (1-5).                    21
-----------------------------------------------------------------------------------------------
Tier II Testing and/or Extrapolation   Subchronic toxicity route-to- ECA Appendix C.2 and                     36
 Reporting.                             route extrapolation of dose-  C.6.
                                        response (oral Tier II
                                        Testing to inhalation) of a
                                        study reported by Daniel et
                                        al. (1994).
                                       Subchronic neurotoxicity      40 CFR 799.9620 (as                      42
                                        (oral).                       annotated in ECA
                                                                      Appendix D.2).
                                       Subchronic neurotoxicity      ECA Appendix C.3 and                     52
                                        route-to-route                C.6.
                                        extrapolation of dose-
                                        response (oral Tier II
                                        Testing to inhalation).
                                       Reproductive toxicity         40 CFR 799.9380 (as                      42
                                        (oral).                       annotated in ECA
                                                                      Appendix D.3).

[[Page 33128]]

 
                                       Reproductive toxicity route-  ECA Appendix C.4 and                     52
                                        to-route extrapolation of     C.6.
                                        dose-response (oral data to
                                        inhalation, including Tier
                                        II Testing and extant
                                        studies reported by Alumot
                                        et al. (1976), Rao et al.
                                        (1980), and Lane et al.
                                        (1982)).
----------------------------------------------------------------------------------------------------------------
\1\ Number of months after the effective date of the Order that incorporates this ECA when the final report is
  due. In addition, every 6 months from the effective date of the Order until the end of the ECA testing
  program, interim reports describing the status of all testing to be performed under this ECA must be submitted
  by the Companies to EPA.

C. What are the Uses for the Test Data for EDC?

    EPA would use the data obtained from testing to implement several 
provisions of section 112 of the Clean Air Act (CAA), including the 
determination of residual risk, the estimation of the risks associated 
with accidental releases of chemicals, and other HAP risk assessments. 
EPA will also use the data from this ECA to fulfill part of the Tier I 
Testing portion of the Voluntary Children's Chemical Evaluation Program 
(VCCEP). (For more information about VCCEP, see: http://www.epa.gov/chemrtk/vceep/.) In addition, the data will be used by other Federal 
agencies (e.g., the Agency for Toxic Substances and Disease Registry 
(ATSDR), the National Institute for Occupational Safety and Health 
(NIOSH), the Occupational Safety and Health Administration (OSHA), and 
the Consumer Product Safety Commission (CPSC)) in assessing chemical 
risks and in taking appropriate actions within their programs (see the 
proposed HAPs test rule at 61 FR 33178, 33179, June 26, 1996).

D. Does the ECA for EDC Meet all the Testing Requirements for EDC that 
were Contained in the Proposed Test Rule?

    In the proposed HAPs test rule, as amended, EPA proposed testing of 
EDC for acute, subchronic, developmental, and reproductive effects and 
neurotoxocity by the inhalation route of exposure. The ECA alternative 
testing program for EDC requires inhalation testing for acute toxicity 
and acute neurotoxicity, and oral drinking water testing for subchronic 
neurotoxicity and reproductive effects toxicity. The ECA requires the 
development of PK/MECH data to support computational PBPK modeling to 
inform quantitative route-to-route extrapolations of dose-response 
(oral to inhalation) for the endpoints of subchronic toxicity, 
subchronic neurotoxicity, and reproductive effects toxicity as 
described in the ECA.
    During discussions to develop this ECA, EPA concluded that the 
developmental toxicity studies reported by Rao et al. (1980; Ref. 11), 
in rabbits, and Payan et al. (1995; Ref. 13), in rats, adequately 
fulfill the HAPs rulemaking testing requirement for developmental 
toxicity testing for EDC and, therefore, the ECA does not require, and 
the final HAPs test rule will not require this testing. In addition, 
the ECA does not require, and the final HAPs test rule will not 
require, macrophage function testing (a component of EPA's acute 
toxicity test gudeline 40 CFR 799.9135) because EPA considers existing 
data by Sherwood et al. (1987; Ref. 14) adequate to fulfill this aspect 
of the acute testing need. Furthermore, the Tier I HAPs Testing 
endpoints (acute toxicity and acute neurotoxicity) will not be included 
in the final HAPs test rule because the route of testing to be 
conducted under this ECA is identical to that specified in the HAPs 
rulemaking. Finally, depending on the outcome of EPA's Program Review, 
the Agency anticipates that the balance of the testing for EDC that was 
contained in the proposed HAPs test rule, as amended, will also not be 
included in the final HAPs test rule because the Companies will conduct 
equivalent testing as Tier II Testing and Extrapolation Reporting under 
this ECA alternative testing program for EDC. Therefore, EPA 
anticipates the fulfilling of all of the health effects testing 
requirements, identified in the HAPs proposed rule, as amended, by 
implementing the ECA and Order.
    The issuance of the ECA and Order constitutes final EPA action for 
purposes of 5 U.S.C. 704.

E. What if EPA Should Require Additional Health Effects Testing on EDC?

    If EPA decides in the future that it requires additional health 
effects data on EDC, the Agency will initiate a separate action.

IV. Other Impacts of the ECA for EDC

    The issuance of the ECA and Order under TSCA section 4 subjects the 
Companies that signed the ECA to export notification requirements under 
TSCA section 12(b)(1), as set forth at 40 CFR part 707, subpart D, if 
they export or intend to export EDC.
    In the 12(b) proposal published in the Federal Register of December 
23, 1997 (62 FR 67038) (FRL-5762-8), EPA proposed to amend 40 CFR 
799.5000 by adding EDC to the list of chemicals subject to testing 
consent orders. The listing of a chemical substance at 40 CFR 799.5000 
serves as notification to all persons who export or intend to export 
the chemical substance that:
    1. The chemical substance is the subject of an ECA and Order.
    2. EPA's export notification regulations at 40 CFR part 707, 
subpart D, apply to those exporters who have signed the ECA, as well as 
those exporters who have not signed the ECA (40 CFR 799.19).
    When a final rule based on the proposed rule is published in the 
Federal Register, all persons who export or who intend to export EDC 
will be subject to export notification requirements.

V. Paperwork Reduction Act

    The ECA and Order announced in this notice do not contain any 
information collection requirements that require additional approval by 
the Office of Management and Budget (OMB) under the Paperwork Reduction 
Act (PRA), 44 U.S.C. 3501 et seq. The information collection 
requirements related to test rules and ECAs issued under TSCA section 4 
have already been approved by OMB under OMB control number 2070-0033 
(EPA ICR No. 1139). The one-time public burden for this collection of 
information is estimated to be approximately 3,364 hours total (Ref. 
15). Under the PRA, ``burden'' means the total time, effort, or 
financial resources expended by persons to generate, maintain, retain, 
or disclose or provide information to or for a Federal agency. For this 
collection it includes the time needed to review instructions; complete 
and review the collection of information; and transmit or otherwise 
disclose the information. An agency

[[Page 33129]]

may not conduct or sponsor, and a person is not required to respond to 
a collection of information unless it displays a currently valid OMB 
control number. The OMB control number for EPA's regulations, after 
initial display in the final rule, are listed in 40 CFR part 9.

VI. References

    1. U.S. EPA, OPPT. I. Ethylene Dichloride (107-06-2). Pp 24-27 In: 
``TSCA Section 4 Findings for 21 Hazardous Air Pollutants: A Supporting 
Document for Proposed Hazardous Air Pollutants (HAPs) Test Rule.'' 
(June 25, 1996).
    2. The HAP Task Force. Letter from Peter E. Voytek to Charles M. 
Auer with attachment entitled: ``Proposal for Pharmacokinetics Study of 
Ethylene Dichloride, November 22, 1996.'' (November 22, 1996).
    3. U.S. EPA. Letter from Charles M. Auer to Peter E. Voytek with 
attachment entitled: ``Preliminary EPA Technical Analysis of Proposed 
Industry Pharmacokinetics (PK) Strategy for Ethylene Dichloride, June, 
1997.'' (June 26, 1997).
    4. The HAP Task Force. Letter from Peter E. Voytek to Charles M. 
Auer, U.S. EPA. (March 19, 1999).
    5. U.S. EPA. Letter from Charles M. Auer to Peter E. Voytek, HAP 
Task Force, Re: ECA Development of Ethylene Dichloride (EDC) (OPPTS 
42197C, with attachment: ``EDC ECA--DRAFT, dated February, 2001.'' 
(February 13, 2001).
    6. Final Enforceable Consent Agreement for Ethylene Dichloride and 
Accompanying Testing Consent Order, signed by EPA on May 13, 2003.
    7. D'Souza, R.W., Francis, W.R., Bruce R.D., and Andersen, M.E. 
Physiologically based phamacokinetic model for ethylene dichloride and 
its application in risk assessment. Pp 286-301, In: Pharmacokinetics in 
Risk Assessment. National Academy Press. Washington, D.C. (1987).
    8. D'Souza, R.W., Francis, W.R., and Andersen, M.E. Physiological 
model for tissue glutathione depletion and increased resynthesis after 
ethylene dichloride exposure. Journal of Pharmacology and Experimental 
Therapeutics 245(2):563-568. 1988.
    9. Daniel, F.B., Robinson, M., Olson, G.R., York, R.G., and Condie, 
L.W. Ten and ninety-day toxicity studies of 1,2-dichloroethane in 
Sprague-Dawley rats. Drug and Chemical Toxicology 17: 463-477. 1994.
    10. Alumot, E., Nachtomi, E., Mandel, E., Holstein, P., Bondi, A., 
and Herzberg, M. Tolerance and acceptable daily intake of chlorinated 
fumigants in the rat diet. Food, Cosmetics and Toxicology 14: 105-110. 
(1976).
    11. Rao, K.S., Murray, J.S., Deacon, M.M., John, J.A., Calhoun, 
L.L., and Young, J.T. Teratogenicity and reproduction studies in 
animals inhaling ethylene dichloride. Banbury Report 5: 149-166. 
(1980).
    12. Lane, R.W., Riddle, B.L., and Borzelleca, J.F. Effects of 1,2-
dichloroethane and 1,1,1-trichloroethane in drinking water on 
reproduction and development in mice. Toxicology and Applied 
Pharmacology 63: 409-421. 1982.
    13. Payan, J.P., Saillenfait, A.M., Bonnet, P., Fabry, J.P., 
Langonne, I., and Sabate J.P. Assessment of the developmental toxicity 
and placental transfer of the 1,2-dichloroethane in rats. Fundamental 
and Applied Toxicology 28: 187-198. 1995.
    14. Sherwood, R.L., O'Shea, W., Thomas, P.T., Ratajczak, H.V., and 
Aranyi, C. Effects of inhalation of ethylene dichloride on pulmonary 
defenses of mice and rats. Toxicology and Applied Pharmacology 91: 491-
496. 1987.
    15. U.S. EPA, OPPTS. ``Burden Estimates for the Enforceable Consent 
Agreement for Ethylene Dichloride.'' (January 31, 2002).

List of Subjects

    Environmental protection, Hazardous chemicals.


    Dated: May 13, 2003.
Stephen Johnson,
 Assistant Administrator for Prevention, Pesticides and Toxic 
Substances.

[FR Doc. 03-13721 Filed 6-2-03; 8:45 am]
BILLING CODE 6560-50-S